These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 27943153)

  • 1. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
    Hubbard JM; Mahoney MR; Loui WS; Roberts LR; Smyrk TC; Gatalica Z; Borad M; Kumar S; Alberts SR
    Target Oncol; 2017 Apr; 12(2):201-209. PubMed ID: 27943153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
    Cai Z; Wang C; Liu P; Shen P; Han Y; Liu N
    Phytomedicine; 2016 Nov; 23(12):1295-1300. PubMed ID: 27765348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
    Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
    Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
    Finn RS; Poon RT; Yau T; Klümpen HJ; Chen LT; Kang YK; Kim TY; Gomez-Martin C; Rodriguez-Lope C; Kunz T; Paquet T; Brandt U; Sellami D; Bruix J
    J Hepatol; 2013 Dec; 59(6):1271-7. PubMed ID: 23928403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
    Ooka Y; Chiba T; Ogasawara S; Arai K; Suzuki E; Tawada A; Yamashita T; Kanai F; Kaneko S; Yokosuka O
    Invest New Drugs; 2014 Aug; 32(4):723-8. PubMed ID: 24599799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
    Cainap C; Qin S; Huang WT; Chung IJ; Pan H; Cheng Y; Kudo M; Kang YK; Chen PJ; Toh HC; Gorbunova V; Eskens FA; Qian J; McKee MD; Ricker JL; Carlson DM; El-Nowiem S
    J Clin Oncol; 2015 Jan; 33(2):172-9. PubMed ID: 25488963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
    Tai WM; Yong WP; Lim C; Low LS; Tham CK; Koh TS; Ng QS; Wang WW; Wang LZ; Hartano S; Thng CH; Huynh H; Lim KT; Toh HC; Goh BC; Choo SP
    Ann Oncol; 2016 Dec; 27(12):2210-2215. PubMed ID: 27681866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
    Lim HY; Heo J; Choi HJ; Lin CY; Yoon JH; Hsu C; Rau KM; Poon RT; Yeo W; Park JW; Tay MH; Hsieh WS; Kappeler C; Rajagopalan P; Krissel H; Jeffers M; Yen CJ; Tak WY
    Clin Cancer Res; 2014 Dec; 20(23):5976-85. PubMed ID: 25294897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib: A Review in Hepatocellular Carcinoma.
    Keating GM
    Target Oncol; 2017 Apr; 12(2):243-253. PubMed ID: 28299600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    Kaneko S; Ikeda K; Matsuzaki Y; Furuse J; Minami H; Okayama Y; Sunaya T; Ito Y; Inuyama L; Okita K
    J Gastroenterol; 2016 Oct; 51(10):1011-21. PubMed ID: 26931117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
    Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
    Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
    Kelley RK; Nimeiri HS; Munster PN; Vergo MT; Huang Y; Li CM; Hwang J; Mulcahy MF; Yeh BM; Kuhn P; Luttgen MS; Grabowsky JA; Stucky-Marshall L; Korn WM; Ko AH; Bergsland EK; Benson AB; Venook AP
    Ann Oncol; 2013 Jul; 24(7):1900-1907. PubMed ID: 23519998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
    J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
    Cheng AL; Kang YK; He AR; Lim HY; Ryoo BY; Hung CH; Sheen IS; Izumi N; Austin T; Wang Q; Greenberg J; Shiratori S; Beckman RA; Kudo M;
    J Hepatol; 2015 Oct; 63(4):896-904. PubMed ID: 26071796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
    Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
    Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.